// App-Quantinova.ai

: Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Researchers

Presenter

  • Michael W. Deininger

Principal Investigators

  • Tim H Brummendorf

  • Jeffrey H. Lipton

  • Dragana Milojkovic

  • Leif Stenke

  • Eric Leip

  • Simon Purcell

  • Andrea Viqueira

  • Jorge E. Cortes

Medical Centers

  • Department of Haematology, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Department of Internal Medicine IV, University Medical Center Aachen, Aachen, Germany

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT

  • Medizinische Klinik IV, Universitätsklinikum RWTH Aachen, Aachen, Germany

  • Hans Messner Allogeneic Blood and Marrow Transplant Unit, Princess Margaret Cancer Centre, Toronto, Canada

  • Department of Hematology, Theme Cancer and Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

Locations

  • United Kingdom

  • Spain

  • Germany

  • United States

  • Sweden

  • Canada

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ischemia Modified Albumin

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved